Redwire Corporation announced that it has successfully 3D bioprinted the first live human heart tissue sample though its 3D BioFabrication Facility (BFF) onboard the International Space Station (ISS). The tissue sample returned to Earth along with the second batch of pharmaceutical crystal experiments from Redwire?s PIL-BOX platform. Redwire?s space biotech capabilities are creating valuable opportunities for the biopharma industry as microgravity allows for outcomes that aren?t possible on Earth, including bioprinting materials that form and hold a three-dimensional shape without the use of scaffolds or additional chemical support.

It is also possible to grow larger and more-highly-ordered pharmaceutical crystals in microgravity. Understanding crystal growth and design can inform the entire drug discovery, development, and design process for small molecule and large biomolecule pharmaceuticals as companies look to deliver new, optimized treatments to help patients. Live human heart tissue bioprinted on Redwire?s BFF could eventually be used to create heart patches as a treatment for damaged heart tissue and opens the door to more effective, personalized medicine.

The tissue sample is now undergoing further testing at Redwire?s facility in Greenville, Indiana. On the next BFF mission, Redwire plans to 3D bioprint human blood vessels in space. Redwire?s second batch of returned PIL-BOX experiments comprised of 36 crystal experiments, which included various crystal molecules designed for pharmaceutical use, with antiviral, antifungal, and antiseizure applications.

These returned crystal experiments were led by Redwire and Butler University.